NNC0487-0111 liver function study is recruiting in Phase 1
A Novo Nordisk A/S Phase 1 registry observation tracks how NNC0487-0111 behaves in people with reduced liver function and normal liver function, with recruiting still open and no results posted yet.
A new Phase 1 registry observation shows Novo Nordisk A/S is still recruiting for a study of NNC0487-0111 in people with reduced liver function and normal liver function, as of 2026-11-10T00:00:00+00:00. For a general reader, the key point is simple: this is an early-stage study looking at how the medicine behaves in the body and how well it is tolerated.
The study is non-randomized and lists four experimental arm groups: Severe hepatic impairment, Moderate hepatic impairment, Mild hepatic impairment, and Normal hepatic impairment. That setup suggests the same medicine is being observed across different liver-function groups, but the registry observation does not say anything about results yet.
This record describes a study and its registry status; study outcomes require posted results.
What the study is measuring
The primary outcome is AUC0-∞, described as the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose. In plain language, that is a way to summarize how much of the drug is in the blood over time after one dose.
The time frame runs from pre-dose on Day 1 up to Day 28, and the description says it is measured as hours\*nanomole per liter (nmol\*h/L). That makes the study especially about drug exposure in the body, not just whether people can take it at all.
AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
Why liver function is central here
The study title itself ties the medicine to reduced liver function and normal liver function, which is the main reason the registry observation stands out. It is not an outcome story, but a design story: the same drug is being tracked across different hepatic impairment groups.
The record also says the primary completion date is 2027-12-01 and the primary completion type is ESTIMATED. That means this is still in progress, so anyone following the study should treat it as an open clinical question rather than a finished answer.
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
How this fits the wider Obesity & Metabolic topic
This registry observation sits inside the active Obesity & Metabolic special event, alongside other ClinicalTrials.gov observations in the same general area. Among them are studies such as Precision Nutrition to Improve Cardiometabolic Health With Dietary (Poly)Phenols and A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
Taken together, these linked studies show a busy pipeline of research around metabolism, weight-related care, and how treatments behave in the body. This specific study adds a liver-function angle to that broader picture, but it remains a recruiting registry observation with no posted results yet.
Registry observation: A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity. (PHASE1, ACTIVE_NOT_RECRUITING)